Advanced Prenatal Therapeutics


Advanced Prenatal Therapeutics, Inc. (APT) has received Breakthrough Medical Device Designation by the US FDA for its novel therapy in development to treat preeclampsia (PE), an unmet need and leading cause of maternal and fetal death worldwide.  APT’s Targeted Apheresis Column for Preeclampsia filters off elevated pathogenic factors associated with causing PE from the pregnant mothers’ blood in a process similar to dialysis, with promise to normalize blood pressure and enable the pregnancy to be prolonged.  APT is also developing a novel PE screening test to ‘rule-in’ high-risk patients as early as the first trimester for enhanced preventive care.